Samjin Pharmaceuticals Co., Ltd. (KRX: 005500)
South Korea flag South Korea · Delayed Price · Currency is KRW
18,780
-210 (-1.11%)
Oct 14, 2024, 3:30 PM KST

Samjin Pharmaceuticals Statistics

Total Valuation

Samjin Pharmaceuticals has a market cap or net worth of KRW 239.91 billion.

Market Cap 239.91B
Enterprise Value n/a

Important Dates

The next estimated earnings date is Tuesday, November 19, 2024.

Earnings Date Nov 19, 2024
Ex-Dividend Date n/a

Share Statistics

Samjin Pharmaceuticals has 12.77 million shares outstanding.

Shares Outstanding 12.77M
Shares Change (YoY) n/a
Shares Change (QoQ) -0.28%
Owned by Insiders (%) 38.99%
Owned by Institutions (%) 1.27%
Float 5.40M

Valuation Ratios

The trailing PE ratio is 10.87.

PE Ratio 10.87
Forward PE n/a
PS Ratio 0.87
PB Ratio 0.90
P/FCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 1.64, with a Debt / Equity ratio of 0.32.

Current Ratio 1.64
Quick Ratio 0.79
Debt / Equity 0.32
Debt / EBITDA 2.65
Debt / FCF -4.85
Interest Coverage 13.15

Financial Efficiency

Return on equity (ROE) is 8.59% and return on invested capital (ROIC) is 4.44%.

Return on Equity (ROE) 8.59%
Return on Assets (ROA) 3.92%
Return on Capital (ROIC) 4.44%
Revenue Per Employee 467.63M
Profits Per Employee 37.36M
Employee Count 586
Asset Turnover 0.74
Inventory Turnover 2.26

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has decreased by -13.68% in the last 52 weeks. The beta is 0.27, so Samjin Pharmaceuticals's price volatility has been lower than the market average.

Beta (5Y) 0.27
52-Week Price Change -13.68%
50-Day Moving Average 18,687.60
200-Day Moving Average 19,870.25
Relative Strength Index (RSI) 62.06
Average Volume (20 Days) 11,403

Short Selling Information

Short Interest n/a
Short Previous Month n/a
Short % of Shares Out n/a
Short % of Float n/a
Short Ratio (days to cover) n/a

Income Statement

In the last 12 months, Samjin Pharmaceuticals had revenue of KRW 274.03 billion and earned 21.89 billion in profits. Earnings per share was 1,727.82.

Revenue 274.03B
Gross Profit 117.73B
Operating Income 23.18B
Pretax Income 25.23B
Net Income 21.89B
EBITDA 33.00B
EBIT 23.18B
Earnings Per Share (EPS) 1,727.82
Full Income Statement

Balance Sheet

The company has 4.66 billion in cash and 87.51 billion in debt, giving a net cash position of -82.85 billion or -6,485.31 per share.

Cash & Cash Equivalents 4.66B
Total Debt 87.51B
Net Cash -82.85B
Net Cash Per Share -6,485.31
Equity (Book Value) 275.86B
Book Value Per Share 20,810.66
Working Capital 52.62B
Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 17.29 billion and capital expenditures -35.35 billion, giving a free cash flow of -18.06 billion.

Operating Cash Flow 17.29B
Capital Expenditures -35.35B
Free Cash Flow -18.06B
FCF Per Share -1,413.77
Full Cash Flow Statement

Margins

Gross margin is 42.96%, with operating and profit margins of 8.46% and 7.99%.

Gross Margin 42.96%
Operating Margin 8.46%
Pretax Margin 9.21%
Profit Margin 7.99%
EBITDA Margin 12.04%
EBIT Margin 8.46%
FCF Margin -6.59%

Dividends & Yields

This stock pays an annual dividend of 800.00, which amounts to a dividend yield of 4.21%.

Dividend Per Share 800.00
Dividend Yield 4.21%
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio 44.95%
Buyback Yield 2.00%
Shareholder Yield 6.21%
Earnings Yield 9.20%
FCF Yield -7.53%
Dividend Details

Stock Splits

The last stock split was on December 29, 2010. It was a forward split with a ratio of 1.0312096.

Last Split Date Dec 29, 2010
Split Type Forward
Split Ratio 1.0312096

Scores

Samjin Pharmaceuticals has an Altman Z-Score of 3.25.

Altman Z-Score 3.25
Piotroski F-Score n/a